Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

ENMD-981693

Generic Name: ENMD-981693

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅N_₇

CAS Number: 934353-76-1

Unique Ingredient Identifier: J6U9WP10T7

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma

Phase 2

Completed

Posted: 2014/09/09

Sponsor:CASI Pharmaceuticals...

ID:NCT02234986

A Study of ENMD-2076 in Ovarian Clear Cell Cancers

Phase 2

Completed

Posted: 2013/08/02

Sponsor:University Health Ne...

ID:NCT01914510

Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma

Phase 2

Completed

Posted: 2012/11/01

Sponsor:University Health Ne...

ID:NCT01719744

Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC

Phase 2

Completed

Posted: 2012/07/12

Sponsor:CASI Pharmaceuticals...

ID:NCT01639248

Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

Phase 2

Completed

Posted: 2010/04/15

Sponsor:CASI Pharmaceuticals...

ID:NCT01104675

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy